This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
In December 2015, Clariant had announced plans to invest CHF 10 million in this Healthcare Packaging plant, that will support the growing generic pharmaceutical industry in India. The investment will be implemented through its wholly owned subsidiary in India.
"The new Healthcare Packaging manufacturing plant here in Cuddalore is another important step within our strategy to intensify growth and increase our market share in the emerging India region by rapidly addressing customer needs," said Christian Kohlpaintner, member of the Clariant Executive Committee.
The new plant will initially produce desiccant canisters and packets, which are inserted into pharmaceutical packaging to control moisture and protect the stability of the medicine during shelf life. The desiccant production area will be Clean Room Class 100,000 and certified ISO 8. It will be compliant with all relevant cGMP and US FDA standards.
"With this new plant, we are responding to our customers' growing demand for high-quality desiccants. This facility will enable us to expand current capacities and provide easy access to potential as well as existing customers in the pharma packaging segment in the India region," said Deepak Parikh, Clariant Region President India.
"This new facility will be integrated into our global Healthcare Packaging manufacturing infrastructure, allowing us to support strong regional demand, and at the same time strengthening our position as the global leader in this segment," added Ketan Premani, Head Clariant Healthcare Packaging Sales.
With ten production sites in Gujarat, Maharashtra, Madhya Pradesh and Tamil Nadu and a state-of-the-art Regional Innovation Center in Mumbai, Clariant's new greenfield plant in Cuddalore will further reinforce its commitment to Make in India and Sell in India. The plant is slated for inauguration in 2017.
